Participants
Contact
La Vanguardia reports on the research performed by Ernest Giralt and Pau Gorostiza in a collaboration project between IRB Barcelona and IBEC. Published in the German journal Angewandte Chemie, the study describes how the scientists have designed peptides that can be controlled through exposure to light. This breakthrough in chemical nanobioengineering may allow the future development of drugs that can be activated in specific parts of the body and at given times, thus reducing their side-effects.
More information in the press release.
Read the article in La Vanguardia (PDF in Catalan, PDF in Spanish).
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
